Atypical hemolytic-uremic syndrome in pregnancy: a case report
Abstract
Introduction: The diagnosis of Atypical hemolytic-uremic syndrome (aHUS) is largely imprecise. Improving outcomes requires accurate diagnosis and timely management. Acute kidney damage, thrombocytopenia, and microangiopathic hemolytic anemia are all signs of aHUS. The condition is brought on by pregnancy, and in genetically susceptible women, it progresses to a terrible hemolytic illness marked by widespread endothelium damage and platelet consumption. The sickness is a potentially fatal ailment that demands quick identification and treatment.
Case Presentation: Our facility provided treatment for severe anemia, thrombocytopenia, and acute renal damage in a 24-year-old G1P1A0 postpartum lady with Caesarean sectio and a HELLP syndrome suspicion. An aHUS diagnosis was later verified. The condition of the patient failed to improve in the first 24 hours after birth. Inside this presence of TMA, the patient began on daily TPE and ran in parallel prednisone medication (1 mg/kg/day). After six TPE cycles, the laboratory values began to rise.
Conclusion: AHUS can be challenging to diagnose early since it frequently mimics other illnesses. To enhance results, proper diagnosis and prompt management are essential. The management strategy includes a multidisciplinary team, early plasmapheresis, and complement inhibition. To lessen the effects of aHUS, TPE should be carried out as soon as feasible on a daily basis.
Keywords
References
Ardissino, G., Longhi, S., Porcaro, L., Pintarelli, G., Strumbo, B., Capone, V., Cresseri, D., Loffredo, G., Tel, F., Salardi, S., Sgarbanti, M., Martelli, L., Rodrigues, E. M., Borsa-Ghiringhelli, N., Montini, G., Seia, M., Cugno, M., Carfagna, F., Consonni, D., & Tedeschi, S. (2021). Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality. Kidney International Reports, 6(6), 1614–1621. https://doi.org/10.1016/j.ekir.2021.03.885
Bhandari, J., & Sedhai, Y. R. (2023). Hemolytic Uremic Syndrome. StatPearls Publishing.
Brocklebank, V., & Kavanagh, D. (2017). Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clinical Kidney Journal, 10(5), 600–624. https://doi.org/10.1093/ckj/sfx081
Bu, F., Borsa, N., Gianluigi, A., & Smith, R. J. H. (2012). Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clinical & Developmental Immunology, 2012, 370426. https://doi.org/10.1155/2012/370426
Cofiell, R., Kukreja, A., Bedard, K., Yan, Y., Mickle, A. P., Ogawa, M., Bedrosian, C. L., & Faas, S. J. (2015). Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood, 125(21), 3253–3262. https://doi.org/10.1182/blood-2014-09-600411
Faguer, S., Huart, A., Fremeaux-Bacchi, V., Ribes, D., & Chauveau, D. (2013). Eculizumab and drug-induced haemolytic-uraemic syndrome. Clinical Kidney Journal, 6(5), 484–485. https://doi.org/10.1093/ckj/sft078
Fakhouri, F., Roumenina, L., Provot, F., Sallée, M., Caillard, S., Couzi, L., Essig, M., Ribes, D., Dragon-Durey, M.-A., Bridoux, F., Rondeau, E., & Frémeaux-Bacchi, V. (2010). Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. Journal of the American Society of Nephrology, 21(5), 859–867. https://doi.org/10.1681/ASN.2009070706
Feitz, W. J. C., van de Kar, N. C. A. J., Orth-Höller, D., van den Heuvel, L. P. J. W., & Licht, C. (2018). The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik e.V, 30(4), 400–409. https://doi.org/10.1007/s11825-018-0216-0
Gurevich, E., & Landau, D. (2023). Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. Pediatric Drugs, 25(2), 193–202. https://doi.org/10.1007/s40272-022-00555-6
Hans, R., Sharma, R. R., Marwaha, N., Suri, D., Kumar, R., Gupta, A., & Singh, S. (2016). Efficacy and safety of therapeutic plasma exchange by using apheresis devices in pediatric atypical hemolytic uremic syndrome patients. Journal of Clinical Apheresis, 31(4), 381–387. https://doi.org/10.1002/jca.21412
Jokiranta, T. S. (2017). HUS and atypical HUS. Blood, 129(21), 2847–2856. https://doi.org/10.1182/blood-2016-11-709865
Le Clech, A., Simon-Tillaux, N., Provôt, F., Delmas, Y., Vieira-Martins, P., Limou, S., Halimi, J.-M., Le Quintrec, M., Lebourg, L., Grangé, S., Karras, A., Ribes, D., Jourde-Chiche, N., Rondeau, E., Frémeaux-Bacchi, V., & Fakhouri, F. (2019). Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International, 95(6), 1443–1452. https://doi.org/10.1016/j.kint.2019.01.023
Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., Karpman, D., Landau, D., Langman, C. B., Lapeyraque, A.-L., Licht, C., Nester, C., Pecoraro, C., Riedl, M., van de Kar, N. C. A. J., Van de Walle, J., … Frémeaux-Bacchi, V. (2016). An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 31(1), 15–39. https://doi.org/10.1007/s00467-015-3076-8
Loirat, C., & Frémeaux-Bacchi, V. (2011). Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Diseases, 6(1), 60. https://doi.org/10.1186/1750-1172-6-60
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015). Complement System Part II: Role in Immunity. Frontiers in Immunology, 6. https://doi.org/10.3389/fimmu.2015.00257
Nester, C. M., Barbour, T., de Cordoba, S. R., Dragon-Durey, M. A., Fremeaux-Bacchi, V., Goodship, T. H. J., Kavanagh, D., Noris, M., Pickering, M., Sanchez-Corral, P., Skerka, C., Zipfel, P., & Smith, R. J. H. (2015). Atypical aHUS: State of the art. Molecular Immunology, 67(1), 31–42. https://doi.org/10.1016/j.molimm.2015.03.246
Noris, M., Bresin, E., Mele, C., & Remuzzi, G. (1993). Genetic Atypical Hemolytic-Uremic Syndrome.
Saad, A., Roman, J., Wyble, A., & Pacheco, L. (2016). Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. American Journal of Perinatology Reports, 06(01), e125–e128. https://doi.org/10.1055/s-0036-1579539
Salvadori, M., & Bertoni, E. (2013). Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World Journal of Nephrology, 2(3), 56–76. https://doi.org/10.5527/wjn.v2.i3.56
Schartz, N. D., & Tenner, A. J. (2020). The good, the bad, and the opportunities of the complement system in neurodegenerative disease. Journal of Neuroinflammation, 17(1), 354. https://doi.org/10.1186/s12974-020-02024-8
Schramm, E. C., Roumenina, L. T., Rybkine, T., Chauvet, S., Vieira-Martins, P., Hue, C., Maga, T., Valoti, E., Wilson, V., Jokiranta, S., Smith, R. J. H., Noris, M., Goodship, T., Atkinson, J. P., & Fremeaux-Bacchi, V. (2015). Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 125(15), 2359–2369. https://doi.org/10.1182/blood-2014-10-609073
Tomazos, I., Garlo, K., Wang, Y., Chen, P., & Laurence, J. (2020). Triggers in Patients with Atypical Hemolytic Uremic Syndrome: An Observational Cohort Study Using a US Claims Database. Blood, 136(Supplement 1), 30–31. https://doi.org/10.1182/blood-2020-136278
Vieira-Martins, P., El Sissy, C., Bordereau, P., Gruber, A., Rosain, J., & Fremeaux-Bacchi, V. (2016). Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science, 54(2), 212–219. https://doi.org/10.1016/j.transci.2016.04.011
Walport, M. J. (2001). Complement. New England Journal of Medicine, 344(14), 1058–1066. https://doi.org/10.1056/NEJM200104053441406
Waters, A. M., & Licht, C. (2011). aHUS caused by complement dysregulation: new therapies on the horizon. Pediatric Nephrology (Berlin, Germany), 26(1), 41–57. https://doi.org/10.1007/s00467-010-1556-4
Wong, E. K. S., Goodship, T. H. J., & Kavanagh, D. (2013). Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology, 56(3), 199–212. https://doi.org/10.1016/j.molimm.2013.05.224
Yan, K., Desai, K., Gullapalli, L., Druyts, E., & Balijepalli, C. (2020). Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clinical Epidemiology, Volume 12, 295–305. https://doi.org/10.2147/CLEP.S245642
Yoshida, Y., Kato, H., Ikeda, Y., & Nangaku, M. (2019). Pathogenesis of Atypical Hemolytic Uremic Syndrome. Journal of Atherosclerosis and Thrombosis, 26(2), 99–110. https://doi.org/10.5551/jat.RV17026
DOI: 10.24815/jks.v23i3.31485
Refbacks
- There are currently no refbacks.